Literature DB >> 16054039

CAR: three new models for a problem child.

David D Moore1.   

Abstract

By comparison with its older and better-behaved cousins in the nuclear receptor superfamily, CAR (NR1I3) has always been an oddball. Three new crystal structures recently described in Molecular Cell reveal the molecular basis for some of its bad habits (Xu et al., 2004; Suino et al., 2004; Shan et al., 2004).

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16054039     DOI: 10.1016/j.cmet.2004.12.006

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  6 in total

Review 1.  Small-molecule modulators of PXR and CAR.

Authors:  Sergio C Chai; Milu T Cherian; Yue-Ming Wang; Taosheng Chen
Journal:  Biochim Biophys Acta       Date:  2016-02-24

2.  Helix 11 dynamics is critical for constitutive androstane receptor activity.

Authors:  Edward Wright; Scott A Busby; Sarah Wisecarver; Jeremy Vincent; Patrick R Griffin; Elias J Fernandez
Journal:  Structure       Date:  2011-01-12       Impact factor: 5.006

Review 3.  Role of CAR and PXR in xenobiotic sensing and metabolism.

Authors:  Yue-Ming Wang; Su Sien Ong; Sergio C Chai; Taosheng Chen
Journal:  Expert Opin Drug Metab Toxicol       Date:  2012-05-03       Impact factor: 4.481

4.  NCOA6 differentially regulates the expression of the CYP2C9 and CYP3A4 genes.

Authors:  Sailesh Surapureddi; Ritu Rana; Joyce A Goldstein
Journal:  Pharmacol Res       Date:  2011-02-01       Impact factor: 7.658

5.  Constitutive androstane receptor agonist, TCPOBOP, attenuates steatohepatitis in the methionine choline-deficient diet-fed mouse.

Authors:  Edwina-S Baskin-Bey; Akira Anan; Hajime Isomoto; Steven-F Bronk; Gregory-J Gores
Journal:  World J Gastroenterol       Date:  2007-11-14       Impact factor: 5.742

6.  Nuclear receptor coactivator 6 mediates the synergistic activation of human cytochrome P-450 2C9 by the constitutive androstane receptor and hepatic nuclear factor-4alpha.

Authors:  Sailesh Surapureddi; Ritu Rana; Janardan K Reddy; Joyce A Goldstein
Journal:  Mol Pharmacol       Date:  2008-06-13       Impact factor: 4.436

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.